Clinical Trial Update: Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration [Phase 1]

View source ↗

Summary

Phase 1 study comparing PK/PD of BIOD-123 and BIOD-125 with Humalog in people with Type 1 diabetes, including assessments of injection site toleration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• BIOD-123
• BIOD-125
• Humalog (insulin lispro)

Snippet

Sponsor: Biodel | Conditions: Diabetes Mellitus | Phase 1 | Status: COMPLETED